BR9507768A - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BR9507768A
BR9507768A BR9507768A BR9507768A BR9507768A BR 9507768 A BR9507768 A BR 9507768A BR 9507768 A BR9507768 A BR 9507768A BR 9507768 A BR9507768 A BR 9507768A BR 9507768 A BR9507768 A BR 9507768A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR9507768A
Other languages
English (en)
Inventor
Lawrence John Penkler
Lueta Ann Glintenkamp
Mark David Bodley
Michiel Coenraad Bo Oudtshoorn
Christopher Stubbs
Original Assignee
Farmarc Nederland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmarc Nederland Bv filed Critical Farmarc Nederland Bv
Publication of BR9507768A publication Critical patent/BR9507768A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9507768A 1994-05-27 1995-05-22 Composição farmacêutica BR9507768A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA943740 1994-05-27
PCT/GB1995/001152 WO1995032737A1 (en) 1994-05-27 1995-05-22 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR9507768A true BR9507768A (pt) 1997-09-02

Family

ID=25583939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507768A BR9507768A (pt) 1994-05-27 1995-05-22 Composição farmacêutica

Country Status (6)

Country Link
EP (1) EP0760680A1 (pt)
JP (1) JPH10500982A (pt)
AU (1) AU2531295A (pt)
BR (1) BR9507768A (pt)
CA (1) CA2190598A1 (pt)
WO (1) WO1995032737A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
DE69628007T2 (de) * 1995-06-07 2003-11-27 Elan Drug Delivery Ltd., Ruddington Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
IT1294205B1 (it) * 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
ATE232382T1 (de) * 1998-09-10 2003-02-15 Nycomed Danmark As Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
EP1543841A4 (en) * 2002-08-15 2011-03-16 Yunqing Liu SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
DE112023000659T5 (de) 2022-01-25 2024-11-14 Leiutis Pharmaceuticals Llp Neue Naproxen-Natrium-Präparate zur parenteralen Verabreichung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT52263B (de) * 1911-04-22 1912-02-26 Jean Baptiste Feilner Verfahren zur Herstellung von photographischen Kombinationsnegativen.
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
WO1991004026A1 (en) * 1989-09-14 1991-04-04 Australian Commercial Research & Development Limited Drug delivery compositions
FR2660195B1 (fr) * 1990-03-28 1994-10-07 Crinex Sa Laboratoires Composition pharmaceutique a macher, antiinflammatoire et/ou analgesique.
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
GB9207990D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Pharmaceutical composition

Also Published As

Publication number Publication date
EP0760680A1 (en) 1997-03-12
WO1995032737A1 (en) 1995-12-07
JPH10500982A (ja) 1998-01-27
AU2531295A (en) 1995-12-21
CA2190598A1 (en) 1995-12-07

Similar Documents

Publication Publication Date Title
FI20071025L (fi) Farmaseuttisia koostumuksia
NO20021172D0 (no) Farmasöytisk sammensetning
FI970995L (fi) Farmaseuttisia yhdisteitä
FI955311L (fi) Farmaseuttinen koostumuspohja
FI944832L (fi) Farmaseuttinen koostumus
FI954243A7 (fi) Farmaseuttiset yhdisteet
ITMI932540A0 (it) Composizione farmaceutica
BR9507768A (pt) Composição farmacêutica
LV11727A (lv) Farmaceitiska kompozicija
FI973229A0 (fi) Uusi farmaseuttinen koostumus
ID18698A (id) Komposisi farmasi
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
FI973280A0 (fi) Farmaseuttinen koostumus
LV10579A (lv) Farmaceitiska kompozicija
FI961364L (fi) Lääkeainekoostumus
ITMI962628A0 (it) Composizione farmaceutica
BR9605777A (pt) Composição farmacêutica
FI954050A7 (fi) Lääkekoostumuksia
FI962738A7 (fi) Farmaseuttiset koostumukset
BR9605131A (pt) Composição farmacêutica
ID23531A (id) Komposisi farmasi
IT1272935B (it) Composizione farmaceutica contenente n-acetil-cisteina
SE9402924D0 (sv) Novel pharmaceutical composition
SE9402437D0 (sv) Pharmaceutical composition
KR960016881A (ko) 제약 조성물

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law